Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Triple Negative Breast Neoplasms
Interventions: DRUG: Dasatinib|PROCEDURE: Conventional Surgery|OTHER: Laboratory Biomarker Analysis
Sponsor: University of Wisconsin, Madison
Collaborators: National Cancer Institute (NCI)